Horizon Scanning in Oncology - Reports

Decision Support Documents

Within the scope of the Horizon Scanning in Oncology project, the LBI-HTA periodically publishes assessments on novel cancer drugs with a likely therapeutical and/or financial outcome. These assessments serve as decision aids for funding agencies and the decision-making network "HTA in hospitals " alike.
 

Publication series (in English):

DSD HSO No. 87
Atezolizumab (Tecentriq®) with nab-paclitaxel (Abraxane®) for the treatment of advanced triple-negative breast cancer (aTNBC) New!

DSD HSO No. 86
Olaparib (Lynparza®) as first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer' New!

DSD HSO No. 85
Ibrutinib (Imbruvica®) in combination with rituximab for the treatment of Waldenström’s macroglobulinemia

DSD HSO No. 84
Enzalutamide (Xtandi®) in patients with nonmetastatic, castration-resistant prostate cancer (CRPC)

DSD HSO No. 83
Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer (NSCLC)

DSD HSO No. 82
Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the first-line treatment of patients with advanced RCC

DSD HSO No. 81
Daratumumab (Darzalex®) in combination with bortezomib, melphalan and prednisone for untreated myeloma

DSD HSO No. 80
Osimertinib (Tagrisso®) for the initial treatment of EGFR-mutated advanced non–small-cell lung cancer (NSCLC) New!

DSD HSO No. 79
Rituximab (MabThera®) after autologous stem-cell transplantation (ASCT) in mantle cell lymphoma (MCL)

DSD HSO No. 78
Abemaciclib (Verzenio®) in combination with a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for advanced breast cancer (ABC)

DSD HSO No. 77
Alectinib as monotherapy for the first-line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)

DSD HSO No. 76
Durvalumab (Imfinzi™) for the treatment of patients with stage III non-small-cell lung cancer after prior chemoradiotherapy

DSD HSO No. 75
Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC)

DSD HSO No. 74
Midostaurin with standard chemotherapy in FLT3-Positive Acute Myeloid Leukaemia 

DSD HSO No. 73
Regorafenib indicated  as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib  

DSD HSO No. 72
Abemaciclib (Verzenio®) in combination with fulvestrant for treatment of HR-positive, HER2-negative advanced breast cancer (ABC) 

DSD HSO No. 71
Olaparib (Lynparza®) in patients with BRCA-mutated metastatic breast cancer 

DSD HSO No. 70
Pembrolizumab (Keytruda®) as second-line treatment for patients with advanced urothelial carcinoma (UC)

DSD HSO No. 69
Ceritinib (Zykadia®) as first-line therapy for patients with advanced ALK-positive non-small cell lung cancer

DSD HSO No. 68
Atezolizumab (Tecentriq®) in previously treated non-small cell lung cancer (NSCLC)

DSD HSO No. 67
Ipilimumab (Yervoy®) in the adjuvant therapy for high-risk stage III cutaneous melanoma

DSD HSO No. 66
Neratinib for the treatment of patients with HER2-positive breast cancer after trastuzumab-based adjuvant therapy

DSD HSO No. 65
Ribociclib in combination with letrozole for the first-line therapy of HR-positive, HER2-negative recurrent or metastatic breast cancer

DSD HSO No. 64
Palbociclib (Ibrance®) in combination with fulvestrant for the treatment of hormone-receptor-positive, HER2-negative advanced or metastatic breast cancer

DSD HSO No. 63
Ixazomib (Ninlaro®) in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma (MM)

DSD HSO No. 62
Venetoclax (Venclexta^TM) for the treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) with chromosome 17p deletion

DSD HSO No. 61
Atezolizumab (Tecentriq^TM) for the treatment of locally advanced and metastatic urothelial carcinoma 

DSD HSO No. 60
Obinutuzumab (Gazyvaro®) in combination with bendamustine for the treatment of relapsed/refractory follicular lymphoma (FL)

DSD HSO No. 59
Afatinib (Giotrif®) in patients with non-small cell lung cancer (NSCLC) who are refractory to erlotinib/gefitinib and afatinib monotherapy

DSD HSO No. 58
Pembrolizumab (Keytruda®) in previously treated advanced non-small cell lung cancer (NSCLC)

DSD HSO No. 57
Ofatumumab (Arzerra®) as maintenance therapy in patients with relapsed chronic lymphocytic leukaemia (CLL)

DSD HSO No. 56
Bevacizumab (Avastin®) in addition to standard chemotherapy for the first-line treatment of ovarian cancer

DSD HSO No. 55
Pembrolizumab (Keytruda®) for the treatment of advanced melanoma

DSD HSO No. 54
Ramucirumab in combination with paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction carcinoma

DSD HSO No. 53
Nivolumab (Nivolumab BMS®) for the second-line therapy of metastatic squamous non-small cell lung cancer

DSD HSO No. 52
Carfilzomib (Kyprolis®) for patients with relapsed multiple myeloma who have received one to three prior lines of therapy

DSD HSO No. 51
Bevacizumab (Avastin®) in combination with chemotherapy as second-line therapy for HER2-negative, locally recurrent or metastatic breast cancer that has progressed after first-line treatment with bevacizumab plus chemotherapy

DSD HSO No. 50
Nivolumab (Opdivo®) as single-agent first-line therapy for unresectable or metastatic melanoma

DSD HSO No. 49
Idelalisib (Zydelig®) in addition to rituximab for the treatment of relapsed chronic lymphocytic leukaemia

DSD HSO No. 48
Bevacizumab (Avastin®) for platinum-resistant recurrent, epithelial ovarian, fallopian tube or primary peritoneal cancer

DSD HSO No. 47
Ibrutinib (Imbruvica®) for relapsed or refractory chronic lymphocytic leukaemia

DSD HSO No. 46
Bevacizumab (Avastin®) as maintenance therapy after first progression on bevacizumab for patients with advanced colorectal carcinoma

DSD HSO No. 45
Obinutuzumab (Gazyva®) for previously untreated patients with chronic lymphocytic leukaemia (CLL)

DSD HSO No. 44
Radium-223 dichloride (Xofigo®) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease

DSD HSO No. 43
Nab-Paclitaxel (Abraxane®) as first-line therapy for metastatic adenocarcinoma of the pancreas

DSD HSO No. 42
Dabrafenib (Tafinlar®) in previously untreated subjects with BRAF mutation-positive advanced (stage III) or metastatic (stage IV) melanoma

DSD HSO No. 41
Afatinib (Giotrif®) for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s)

DSD HSO No. 40
Regorafenib (Stivarga®) for heavily pretreated patients with metastatic colorectal cancer (mCRC)

DSD HSO No. 39
Pomalidomide (Pomalyst®) for the ? 3rd-line therapy of patients with relapsed and refractory multiple myeloma

DSD HSO No. 38
Aflibercept (Zaltrap®) in addition to FOLFIRI for the 2nd line therapy of metastatic colorectal cancer

DSD HSO No. 37
Enzalutamide (Xtandi®) for patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy

DSD HSO No. 36
Trastuzumab emtansine (KadcylaTM) for previously treated patients with
HER2-positive advanced/ metastatic breast cancer

DSD HSO No. 35
Crizotinib (Xalkori®) for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)

DSD HSO No. 34
Trametinib for advanced or metastatic BRAF V600 mutation-positive melanoma

DSD HSO No. 33
Lenalidomide (Revlimid®) for the first-line therapy of transplant-ineligible patients with multiple myeloma

DSD HSO No. 32
Everolimus (Afinitor® or Votubia®) in combination with exemestane in postmenopausal women with oestrogen receptor positive, HER2-negative locally advanced or metastatic breast cancer who are refractory to letrozole or anastrozole

DSD HSO No. 31
Pertuzumab (Omnitarg/Perjeta®) for the first-line therapy of metastatic HER2 positive breast cancer

DSD HSO No. 30
Ipilimumab (Yervoy®) for the first-line therapy of advanced/metastatic cutaneous melanoma

DSD HSO No. 29
Bortezomib (Velcade®) as consolidation or maintenance therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma

DSD HSO No. 28
Lenalidomide (Revlimid®) for the treatment of low /intermediate-1 risk myelodysplastic syndrome with chromosome 5q deletion

DSD HSO No. 27
Bevacizumab (Avastin®) in combination with chemotherapy in previously treated metastatic breast cancer

DSD HSO No. 26
Brentuximab (Adcetris®) for the treatment of relapsed Hodgkin’s lymphoma (HL) or relapsed systemic anaplastic large cell lymphoma (sALCL)

DSD HSO No. 25
Romidepsin (Istodax®) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) after prior systemic therapy  

DSD HSO No. 24
Everolimus (Afinitor®) for the treatment of unresectable or metastatic neuroendocrine tumours of pancreatic origin

DSD HSO No. 23
Vemurafenib for patients with BRAF V600E mutation positive advanced/metastatic melanoma

DSD HSO No. 22
Erlotinib (Tarceva®) for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations

DSD HSO No. 21
Axitinib (AG013736, Inlyta®) for the second-line treatment of metastatic renal cell carcinoma (mRCC)

DSD HSO No. 20
Abiraterone acetate (Zytiga^TM) as 2nd-line therapy for the treatment of metastatic castration-resistant prostate cancer after docetaxel therapy

DSD HSO No. 19
S-1 (TeysunoTM) as first-line therapy for patients with advanced non-small cell lung cancer

DSD HSO No. 18
Eribulin (Halaven®) as third- or late- line mono-therapy for advanced/metastatic breast cancer

DSD HSO No. 17
Dasatinib (Sprycel®) for the 1st-line treatment of Philadelphia-chromosome positive chronic myeloid leukemia in the chronic phase

DSD HSO No. 16
Second-line chemotherapy with cabazitaxel (Jevtana®) for the treatment of castration-resistant metastatic prostate cancer

DSD HSO No. 15
Nilotinib (Tasigna®) for the 1st-line treatment of Philadelphia chromosome positive chronic myeloid leukemia in the chronic phase

DSD HSO No. 14
Ipilimumab for pre-treated patients with advanced/metastatic melanoma

DSD HSO No. 13
Pazopanib (Votrient®) for the treatment of locally advanced and/or metastatic renal cell carcinoma

DSD HSO No. 12
Trastuzumab (Herceptin®) in addition to standard chemotherapy as first-line therapy for advanced gastric cancer

DSD HSO No. 11
Panitumumab (Vectibix®) for the first-line treatment of metastatic colorectal cancer

DSD HSO No. 11/ 1st update 2011
Panitumumab (Vectibix®) as 1st-line combination therapy for the treatment of WT KRAS metastatic colorectal cancer

DSD HSO No. 10
Bendamustine (Ribomustin®/Treanda®/ Levact®) for indolent non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukaemia (CLL) and multiple myeloma

DSD HSO No. 9
Lapatinib ditosylate (Tyverb/Tykerb®) as first-line therapy for the treatment of advanced/metastatic breast cancer

DSD HSO No. 8
Plerixafor (Mozobil®) for autologous stem cell transplantation in patients with lymphoma and multiple myeloma

DSD HSO No. 7
Trabectedin (Yondelis®) for second-line recurrent platinum-sensitive ovarian cancer

DSD HSO No. 6
Gefitinib (Iressa®) for the first-line treatment of non-small cell lung cancer

DSD HSO No. 6/ 1st update 2011
Gefitinib (Iressa®) for the 1st-line treatment of non-small cell lung cancer – 1st Update 2011

DSD HSO No. 5
Ibritumomab tiuxetan (Zevalin®) as consolidation therapy after first remission in patients with follicular lymphoma

DSD HSO No. 4
Rituximab (Rituxan®/MabThera®) for the first- and second-line treatment of chronic lymphocytic leukaemia

DSD HSO No.4/ 1st update 2011
Rituximab (Rituxan®/MabThera®) for the first- and second-line treatment of chronic lymphocytic leukaemia – 1st Update 2011

DSD HSO No. 3
Everolimus (Afinitor®) for the treatment of advanced/metastatic kidney cancer

DSD HSO No. 2
Cetuximab (Erbitux®) in EGFR-expressing Non-Small Cell Lung Cancer

DSD HSO No. 1
Azacitidine (Vidaza®) for the treatment of myelodysplastic syndromes

Contact: Nicole Grössmann